Serum Institute of India (SII) CEO Adar Poonawalla on Saturday said clinical trials of COVID-19 vaccine Covovax have begun in India and the company hopes to launch it by September this year.
In August 2020, American vaccine company Novavax, Inc had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate, in low and middle-income countries and India.
"Covovax trials finally begin in India; the vaccine is made through a partnership with @Novavax and @SerumInstIndia. It has been tested against African and UK variants of #COVID19 and has an overall efficacy of 89%. Hope to launch by September 2021!," Poonawalla said in a tweet.
Pro Kabaddi League: Puneri Paltan Storms Into Final After Beating Telugu Titans
'Will Stop Trains If...': Former Minister Bachu Kadu After Bombay HC Orders To Vacate Wardha Road Amid Farm Loan Waiver Protest In Nagpur- VIDEO
BMC Elections 2025: Lottery To Determine Reservation To Be Drawn On November 11, Final List To Be Published On November 28
Florida Governor DeSantis Orders End Of H-1B Visa Use In State Universities
